Sigma Advanced Systems Limited has completed the divestment of its entire 36.52 per cent equity stake in Extrovis AG, a Switzerland-based pharmaceutical company, for $15 million (about ₹137.61 crore).
The company said this divestment would provide it with additional financial flexibility as it would accelerate the expansion of its aerospace and defence business.
“The divestment forms part of Sigma’s ongoing portfolio rationalisation strategy. We have turned into a pure-play aerospace and defence platform,” a company spokesperson said.
“The divestment of our stake in Extrovis AG is a deliberate step in sharpening Sigma’s focus as a global aerospace and defence manufacturing company,” Sunil Kalidindi, CEO of Sigma Advanced Systems, said.
He said that the transaction strengthened its balance sheet and gave it greater flexibility to invest in new capabilities, pursue strategic opportunities, and support the next phase of Sigma’s growth.
Recently, the company acquired Delhi-based AS Strategic, a defence and space-focused firm with deep roots in Europe.
Orders booked
The Hyderabad-based company secured new orders worth about ₹100 crore from the Ministry of Defence and associated Defence public sector units.
Published on April 22, 2026